Nothing Special   »   [go: up one dir, main page]

de Boer et al., 2002 - Google Patents

A low number of retrieved oocytes at in vitro fertilization treatment is predictive of early menopause

de Boer et al., 2002

View HTML
Document ID
17787597209746659182
Author
de Boer E
den Tonkelaar I
te Velde E
Burger C
Klip H
van Leeuwen F
OMEGA-Project Group
et al.
Publication year
Publication venue
Fertility and sterility

External Links

Snippet

Objective: To investigate whether women with a low number of retrieved oocytes at the first in vitro fertilization (IVF) attempt have an increased risk of early menopause. Design: Nested case-control study. Setting: Twelve IVF clinics in the Netherlands. Patient (s): Women …
Continue reading at www.sciencedirect.com (HTML) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06F—ELECTRICAL DIGITAL DATA PROCESSING
    • G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
    • G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
    • G06F19/34—Computer-assisted medical diagnosis or treatment, e.g. computerised prescription or delivery of medication or diets, computerised local control of medical devices, medical expert systems or telemedicine
    • G06F19/3431—Calculating a health index for the patient, e.g. for risk assessment

Similar Documents

Publication Publication Date Title
de Boer et al. A low number of retrieved oocytes at in vitro fertilization treatment is predictive of early menopause
Lambrinoudaki et al. Premature ovarian insufficiency: a toolkit for the primary care physician
Imani et al. A nomogram to predict the probability of live birth after clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility
Eugster et al. Psychological aspects of in vitro fertilization: a review
Somigliana et al. Age-related infertility and unexplained infertility: an intricate clinical dilemma
Klonoff-Cohen et al. A prospective study of stress among women undergoing in vitro fertilization or gamete intrafallopian transfer
Birch Petersen et al. Ovarian reserve assessment in users of oral contraception seeking fertility advice on their reproductive lifespan
Klonoff-Cohen et al. Effects of maternal and paternal alcohol consumption on the success rates of in vitro fertilization and gamete intrafallopian transfer
Yilmaz et al. Dehydroepiandrosterone supplementation improves predictive markers for diminished ovarian reserve: serum AMH, inhibin B and antral follicle count
US9205092B2 (en) Androgen treatment in females
Copperman Antagonists in poor-responder patients
Gubert et al. Number of motile spermatozoa inseminated and pregnancy outcomes in intrauterine insemination
Decanter et al. First intention IVF protocol for polycystic ovaries: does oral contraceptive pill pretreatment influence COH outcome?
CA2776926C (en) Androgen treatment in females
Goverde et al. Further considerations on natural or mild hyperstimulation cycles for intrauterine insemination treatment: effects on pregnancy and multiple pregnancy rates
Homburg Ovulation induction and controlled ovarian stimulation
Heidar et al. Prediction of different ovarian responses using anti-Müllerian hormone following a long agonist treatment protocol for IVF
Hernández-Díaz et al. Gestational hypertension in pregnancies supported by infertility treatments: role of infertility, treatments, and multiple gestations
Nesbit et al. Ovulation induction and intrauterine insemination in women of advanced reproductive age: a systematic review of the literature
Igwegbe et al. Polycystic ovary syndrome: a review of management outcomes in a low resource setting
Smith et al. Treatment of infertility in women
Zippl et al. Predicting success of intrauterine insemination using a clinically based scoring system
Gitman et al. Pregnancy outcomes of women with multiple sclerosis treated with ocrelizumab in canada: a descriptive analysis of real-world data
De Brucker et al. Assisted reproduction using donor spermatozoa in women aged 40 and above: the high road or the low road?
De Brucker et al. Assisted reproduction counseling in women aged 40 and above: a cohort study